Phaseline

Targets › PPIA

PPIA (Peptidyl-prolyl cis-trans isomerase A): drug programs, companies and trials

1 program from 1 company in 11 trials: 7 Phase 2, 2 Phase 3, 2 Phase 4; Cardiovascular, Genitourinary, Hematology.

Catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Exerts a strong chemotactic effect on leukocytes partly through activation of one of its membrane receptors BSG/CD147, initiating a signaling cascade that culminates in MAPK/ERK activation. (UniProt, P62937)

Open in Phaseline: the race on PPIA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhaoke (Guangzhou) Ophthalmology PharmaceuticalCyclosporine
Cyclophilin A modulator
PPIAPhase 3Moderate to Severe Dry Eye; Meibomian Gland Dysfunction (MGD); Alopecia Areata(AA); Primary Autoimmune Hemolytic Anemia …–

Conditions

Moderate to Severe Dry Eye (1) Meibomian Gland Dysfunction (MGD) (1) Alopecia Areata(AA) (1) Primary Autoimmune Hemolytic Anemia (1) Takotsubo Cardiomyopathy (1) Chronic Myeloproliferative Disorders (1) Type 1 Diabetes (1) Nephrotic Syndrome (1) Aplastic Anemia (1) Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (1) Severe Aplastic Anemia (1)

Modalities

small molecule (1)

Companies

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.